COVID-19 Impact on Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, Market Insights and Forecast to 2026

COVID-19 Impact on Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, Market Insights and Forecast to 2026

Jun 2020 QYResearch Pharmaceutical116 Pages Price :
$ 3900
Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

Segment by Type, the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market is segmented into
Preface
Eluxadoline
Alosetron
Rifaximin
Loperamide
Diphenoxylate + Atropine
Dicyclomine and Hyoscyamine

Segment by Application, the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market is segmented into
Hospitals
Clinics
Others

Regional and Country-level Analysis
The Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share Analysis
Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs business, the date to enter into the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market, Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs product introduction, recent developments, etc.
The major vendors covered:
Astellas Pharmaceuticals
Actavis
Pfizer
GlaxoSmithKline
Salix Pharmaceuticals Ltd
AstraZenenca
...
1 Study Coverage
1.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Introduction
1.2 Market Segments
1.3 Key Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Growth Rate by Type
1.4.2 Preface
1.4.3 Eluxadoline
1.4.4 Alosetron
1.4.5 Rifaximin
1.4.6 Loperamide
1.4.7 Diphenoxylate + Atropine
1.4.8 Dicyclomine and Hyoscyamine
1.5 Market by Application
1.5.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Growth Rate by Application
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Others
1.6 Coronavirus Disease 2019 (Covid-19): Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Impact
1.6.1 How the Covid-19 is Affecting the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry
1.6.1.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered

2 Executive Summary
2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Estimates and Forecasts
2.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue 2015-2026
2.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales 2015-2026
2.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Region: 2020 Versus 2026
2.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Competitor Landscape by Players
3.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Manufacturers
3.1.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Manufacturers (2015-2020)
3.1.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Manufacturers
3.2.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue in 2019
3.2.5 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Manufacturers
3.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Base Distribution, Product Types
3.4.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)
4.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Type (2015-2020)
4.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2015-2020)
4.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2015-2020)
4.1.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Breakdown Data by Application (2015-2026)
5.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Application (2015-2020)
5.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2015-2020)
5.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application (2015-2020)
5.1.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Application (2015-2020)
5.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price Forecast by Application (2021-2026)

6 North America
6.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Country
6.1.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country
6.1.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Type
6.3 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Application

7 Europe
7.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Country
7.1.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country
7.1.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Type
7.3 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Application

8 Asia Pacific
8.1 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Region
8.1.1 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region
8.1.2 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Type
8.3 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Application

9 Latin America
9.1 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Country
9.1.1 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country
9.1.2 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Type
9.3 Central & South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Application

10 Middle East and Africa
10.1 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Country
10.1.1 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country
10.1.2 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Type
10.3 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Application

11 Company Profiles
11.1 Astellas Pharmaceuticals
11.1.1 Astellas Pharmaceuticals Corporation Information
11.1.2 Astellas Pharmaceuticals Description, Business Overview and Total Revenue
11.1.3 Astellas Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Products Offered
11.1.5 Astellas Pharmaceuticals Recent Development
11.2 Actavis
11.2.1 Actavis Corporation Information
11.2.2 Actavis Description, Business Overview and Total Revenue
11.2.3 Actavis Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Products Offered
11.2.5 Actavis Recent Development
11.3 Pfizer
11.3.1 Pfizer Corporation Information
11.3.2 Pfizer Description, Business Overview and Total Revenue
11.3.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Products Offered
11.3.5 Pfizer Recent Development
11.4 GlaxoSmithKline
11.4.1 GlaxoSmithKline Corporation Information
11.4.2 GlaxoSmithKline Description, Business Overview and Total Revenue
11.4.3 GlaxoSmithKline Sales, Revenue and Gross Margin (2015-2020)
11.4.4 GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Products Offered
11.4.5 GlaxoSmithKline Recent Development
11.5 Salix Pharmaceuticals Ltd
11.5.1 Salix Pharmaceuticals Ltd Corporation Information
11.5.2 Salix Pharmaceuticals Ltd Description, Business Overview and Total Revenue
11.5.3 Salix Pharmaceuticals Ltd Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Products Offered
11.5.5 Salix Pharmaceuticals Ltd Recent Development
11.6 AstraZenenca
11.6.1 AstraZenenca Corporation Information
11.6.2 AstraZenenca Description, Business Overview and Total Revenue
11.6.3 AstraZenenca Sales, Revenue and Gross Margin (2015-2020)
11.6.4 AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Products Offered
11.6.5 AstraZenenca Recent Development
11.1 Astellas Pharmaceuticals
11.1.1 Astellas Pharmaceuticals Corporation Information
11.1.2 Astellas Pharmaceuticals Description, Business Overview and Total Revenue
11.1.3 Astellas Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Products Offered
11.1.5 Astellas Pharmaceuticals Recent Development

12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Estimates and Projections by Region
12.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Regions 2021-2026
12.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast by Regions 2021-2026
12.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Forecast (2021-2026)
12.2.1 North America: Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast (2021-2026)
12.2.2 North America: Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast (2021-2026)
12.2.3 North America: Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Forecast by Country (2021-2026)
12.3 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Forecast (2021-2026)
12.3.1 Europe: Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast (2021-2026)
12.3.2 Europe: Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast (2021-2026)
12.3.3 Europe: Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Forecast by Region (2021-2026)
12.5 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Forecast (2021-2026)
12.5.1 Latin America: Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast (2021-2026)
12.5.2 Latin America: Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast (2021-2026)
12.5.3 Latin America: Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porters Five Forces Analysis
13.5 Primary Interviews with Key Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details

List of Table

List of Tables
Table 1. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Segments
Table 2. Ranking of Global Top Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Growth Rate by Type 2020-2026 (K MT) & (US$ Million)
Table 4. Major Manufacturers of Preface
Table 5. Major Manufacturers of Eluxadoline
Table 6. Major Manufacturers of Alosetron
Table 7. Major Manufacturers of Rifaximin
Table 8. Major Manufacturers of Loperamide
Table 9. Major Manufacturers of Diphenoxylate + Atropine
Table 10. Major Manufacturers of Dicyclomine and Hyoscyamine
Table 11. COVID-19 Impact Global Market: (Four Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Forecast Scenarios)
Table 12. Opportunities and Trends for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Players in the COVID-19 Landscape
Table 13. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 14. Key Regions/Countries Measures against Covid-19 Impact
Table 15. Proposal for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Players to Combat Covid-19 Impact
Table 16. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Growth Rate by Application 2020-2026 (K MT)
Table 17. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Region (K MT) & (US$ Million): 2020 VS 2026
Table 18. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Regions 2015-2020 (K MT)
Table 19. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Regions (2015-2020)
Table 20. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Regions 2015-2020 (US$ Million)
Table 21. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Manufacturers (2015-2020) (K MT)
Table 22. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by Manufacturers (2015-2020)
Table 23. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 24. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs as of 2019)
Table 25. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Manufacturers (2015-2020) (US$ Million)
Table 26. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Manufacturers (2015-2020)
Table 27. Key Manufacturers Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (2015-2020) (USD/MT)
Table 28. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table 29. Manufacturers Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Type
Table 30. Date of International Manufacturers Enter into Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market
Table 31. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 32. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2015-2020) (K MT)
Table 33. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by Type (2015-2020)
Table 34. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2015-2020) (US$ Million)
Table 35. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Type (2015-2020)
Table 36. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Selling Price (ASP) by Type 2015-2020 (USD/MT)
Table 37. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2015-2020) (K MT)
Table 38. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by Application (2015-2020)
Table 39. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2015-2020) (K MT)
Table 40. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2015-2020)
Table 41. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2015-2020) (US$ Million)
Table 42. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country (2015-2020)
Table 43. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2015-2020) (K MT)
Table 44. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2015-2020)
Table 45. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2015-2020) (K MT)
Table 46. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Application (2015-2020)
Table 47. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2015-2020) (K MT)
Table 48. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2015-2020)
Table 49. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2015-2020) (US$ Million)
Table 50. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country (2015-2020)
Table 51. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2015-2020) (K MT)
Table 52. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2015-2020)
Table 53. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2015-2020) (K MT)
Table 54. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Application (2015-2020)
Table 55. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2015-2020) (K MT)
Table 56. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region (2015-2020)
Table 57. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2015-2020) (US$ Million)
Table 58. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region (2015-2020)
Table 59. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2015-2020) (K MT)
Table 60. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2015-2020)
Table 61. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2015-2020) (K MT)
Table 62. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Application (2015-2020)
Table 63. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2015-2020) (K MT)
Table 64. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2015-2020)
Table 65. Latin Americaa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2015-2020) (US$ Million)
Table 66. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country (2015-2020)
Table 67. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2015-2020) (K MT)
Table 68. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2015-2020)
Table 69. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2015-2020) (K MT)
Table 70. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Application (2015-2020)
Table 71. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2015-2020) (K MT)
Table 72. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2015-2020)
Table 73. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2015-2020) (US$ Million)
Table 74. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country (2015-2020)
Table 75. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2015-2020) (K MT)
Table 76. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2015-2020)
Table 77. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2015-2020) (K MT)
Table 78. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Application (2015-2020)
Table 79. Astellas Pharmaceuticals Corporation Information
Table 80. Astellas Pharmaceuticals Description and Major Businesses
Table 81. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 82. Astellas Pharmaceuticals Product
Table 83. Astellas Pharmaceuticals Recent Development
Table 84. Actavis Corporation Information
Table 85. Actavis Description and Major Businesses
Table 86. Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 87. Actavis Product
Table 88. Actavis Recent Development
Table 89. Pfizer Corporation Information
Table 90. Pfizer Description and Major Businesses
Table 91. Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 92. Pfizer Product
Table 93. Pfizer Recent Development
Table 94. GlaxoSmithKline Corporation Information
Table 95. GlaxoSmithKline Description and Major Businesses
Table 96. GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 97. GlaxoSmithKline Product
Table 98. GlaxoSmithKline Recent Development
Table 99. Salix Pharmaceuticals Ltd Corporation Information
Table 100. Salix Pharmaceuticals Ltd Description and Major Businesses
Table 101. Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 102. Salix Pharmaceuticals Ltd Product
Table 103. Salix Pharmaceuticals Ltd Recent Development
Table 104. AstraZenenca Corporation Information
Table 105. AstraZenenca Description and Major Businesses
Table 106. AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 107. AstraZenenca Product
Table 108. AstraZenenca Recent Development
Table 109. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Regions (2021-2026) (K MT)
Table 110. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share Forecast by Regions (2021-2026)
Table 111. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 112. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share Forecast by Regions (2021-2026)
Table 113. North America: Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Country (2021-2026) (K MT)
Table 114. North America: Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 115. Europe: Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Country (2021-2026) (K MT)
Table 116. Europe: Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 117. Asia Pacific: Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Region (2021-2026) (K MT)
Table 118. Asia Pacific: Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast by Region (2021-2026) (US$ Million)
Table 119. Latin America: Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Country (2021-2026) (K MT)
Table 120. Latin America: Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 121. Middle East and Africa: Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Country (2021-2026) (K MT)
Table 122. Middle East and Africa: Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 123. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 124. Key Challenges
Table 125. Market Risks
Table 126. Main Points Interviewed from Key Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Players
Table 127. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Customers List
Table 128. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Distributors List
Table 129. Research Programs/Design for This Report
Table 130. Key Data Information from Secondary Sources
Table 131. Key Data Information from Primary Sources
List of Figures
Figure 1. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Picture
Figure 2. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Preface Product Picture
Figure 4. Eluxadoline Product Picture
Figure 5. Alosetron Product Picture
Figure 6. Rifaximin Product Picture
Figure 7. Loperamide Product Picture
Figure 8. Diphenoxylate + Atropine Product Picture
Figure 9. Dicyclomine and Hyoscyamine Product Picture
Figure 10. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Application in 2020 & 2026
Figure 11. Hospitals
Figure 12. Clinics
Figure 13. Others
Figure 14. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Report Years Considered
Figure 15. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size 2015-2026 (US$ Million)
Figure 16. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales 2015-2026 (K MT)
Figure 17. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Market Share by Region: 2020 Versus 2026
Figure 18. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region (2015-2020)
Figure 19. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region in 2019
Figure 20. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region (2015-2020)
Figure 21. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region in 2019
Figure 22. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by Manufacturer in 2019
Figure 23. The Top 10 and 5 Players Market Share by Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue in 2019
Figure 24. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 25. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2015-2020)
Figure 26. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type in 2019
Figure 27. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Type (2015-2020)
Figure 28. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Type in 2019
Figure 29. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share by Price Range (2015-2020)
Figure 30. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Application (2015-2020)
Figure 31. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Application in 2019
Figure 32. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Application (2015-2020)
Figure 33. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Application in 2019
Figure 34. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 35. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 36. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country in 2019
Figure 37. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country in 2019
Figure 38. U.S. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 39. U.S. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 40. Canada Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 41. Canada Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 42. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share by Type in 2019
Figure 43. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share by Application in 2019
Figure 44. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 45. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 46. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country in 2019
Figure 47. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country in 2019
Figure 48. Germany Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 49. Germany Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. France Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 51. France Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. U.K. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 53. U.K. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Italy Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 55. Italy Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 56. Russia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 57. Russia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 58. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share by Type in 2019
Figure 59. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share by Application in 2019
Figure 60. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 61. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 62. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region in 2019
Figure 63. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region in 2019
Figure 64. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 65. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 67. Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. South Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 69. South Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 71. India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 73. Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Taiwan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 75. Taiwan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Indonesia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 77. Indonesia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Thailand Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 79. Thailand Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Malaysia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 81. Malaysia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Philippines Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 83. Philippines Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 84. Vietnam Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 85. Vietnam Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 86. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share by Type in 2019
Figure 87. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share by Application in 2019
Figure 88. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 89. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 90. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country in 2019
Figure 91. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country in 2019
Figure 92. Mexico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 93. Mexico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 94. Brazil Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 95. Brazil Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 96. Argentina Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 97. Argentina Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 98. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share by Type in 2019
Figure 99. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share by Application in 2019
Figure 100. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 101. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 102. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country in 2019
Figure 103. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country in 2019
Figure 104. Turkey Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 105. Turkey Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 106. Saudi Arabia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 107. Saudi Arabia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 108. U.A.E Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 109. U.A.E Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 110. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share by Type in 2019
Figure 111. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share by Application in 2019
Figure 112. Astellas Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 113. Actavis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 114. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 115. GlaxoSmithKline Total Revenue (US$ Million): 2019 Compared with 2018
Figure 116. Salix Pharmaceuticals Ltd Total Revenue (US$ Million): 2019 Compared with 2018
Figure 117. AstraZenenca Total Revenue (US$ Million): 2019 Compared with 2018
Figure 118. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 119. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 120. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 121. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 122. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 123. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 124. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 125. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 126. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 127. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 128. Porter's Five Forces Analysis
Figure 129. Channels of Distribution
Figure 130. Distributors Profiles
Figure 131. Bottom-up and Top-down Approaches for This Report
Figure 132. Data Triangulation
Figure 133. Key Executives Interviewed

Ask for discount before buying this report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Country :
  • Your Requirement
  • Security Code *
* denotes fields which must be completed

Buy This Report


Select License Type :

$ 3900
$ 5850

Do you wish to check sample of this report?

Have Query?


Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email : sales@marketresearchhub.com

Back To Top